Effect of levetiracetam on cerebral oxygenation in neonates
Zeynep Kamil Medical Journal, cilt.56, sa.2, ss.113-118, 2025 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 56 Sayı: 2
- Basım Tarihi: 2025
- Doi Numarası: 10.14744/zkmj.2025.14227
- Dergi Adı: Zeynep Kamil Medical Journal
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.113-118
- Anahtar Kelimeler: Cerebral oxygenation, levetiracetam, near infrared spectroscopy, neonatal seizures
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective: To assess the effect of levetiracetam on cerebral oxygenation in the newborn period, whether it was used as first-line or add-on treatment for neonatal seizures. Material and Methods: A prospective, cross-sectional study was performed. Neonates who were treated with levetiracetam because seizures were suspected clinically were included in the study. The included neonates were clinically stable and preparing for discharge during the study period. Baseline regional cerebral oxygenation (rSO2-C) and cerebral fractional oxygen extraction (FTOE) were recorded one hour before levetiracetam administration; three additional measurements of rSO2-C and FTOE were recorded during levetiracetam administration, and one and two hours after administration. Results: Eighty-one doses of levetiracetam were administered to 22 neonates, and nine (40.9%) of the neonates were receiving phenobarbital together with levetiracetam. The median gestational age and birth weight of the neonates were 37.5 (25–41) weeks and 2755 (720–3740) g, respectively. The levetiracetam dose ranged from 10 mg/kg to 60 mg/kg, with a median value of 20 mg/kg. There were no significant changes in the measurements of rSO2-C and FTOE associated with levetiracetam doses. Conclusion: The impact of levetiracetam on NIRS findings suggests that levetiracetam is safe in the neonatal period in terms of cerebral oxygen metabolism.